Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study

Background: Dupilumab is a fully humanized monoclonal antibody that blocks interleukin-4 and interleukin-13 signals. Several large clinical trials have demonstrated the efficacy of dupilumab in patients with severe asthma. However, few studies have examined a switch to dupilumab from other biologics...

Descripción completa

Detalles Bibliográficos
Autores principales: Higo, Hisao, Ichikawa, Hirohisa, Arakawa, Yukako, Mori, Yoshihiro, Itano, Junko, Taniguchi, Akihiko, Senoo, Satoru, Kimura, Goro, Tanimoto, Yasushi, Miyake, Kohei, Katsuta, Tomoya, Kataoka, Mikio, Maeda, Yoshinobu, Kiura, Katsuyuki, Miyahara, Nobuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455072/
https://www.ncbi.nlm.nih.gov/pubmed/37629217
http://dx.doi.org/10.3390/jcm12165174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455072/
https://www.ncbi.nlm.nih.gov/pubmed/37629217
http://dx.doi.org/10.3390/jcm12165174

Ejemplares similares